Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:KDMN
- CUSIP: N/A
- Web: kadmon.com/
- Market Cap: $175.24 million
- Outstanding Shares: 51,846,000
- 50 Day Moving Avg: $2.62
- 200 Day Moving Avg: $3.62
- 52 Week Range: $2.25 - $11.73
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.85
- P/E Growth: 0.00
- Annual Revenue: $21.96 million
- Price / Sales: 7.98
- Book Value: ($1.13) per share
- Price / Book: -2.99
- EBIDTA: ($98,790,000.00)
- Net Margins: -315.61%
- Return on Assets: -107.98%
- Average Volume: 192,550 shs.
- Short Ratio: 8.01
Frequently Asked Questions for Kadmon Holdings (NASDAQ:KDMN)
What is Kadmon Holdings' stock symbol?
Kadmon Holdings trades on the NASDAQ under the ticker symbol "KDMN."
How were Kadmon Holdings' earnings last quarter?
Kadmon Holdings Inc (NASDAQ:KDMN) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.39) EPS for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.13. The business had revenue of $5.60 million for the quarter, compared to analyst estimates of $4.25 million. The business's revenue for the quarter was down 42.3% on a year-over-year basis. View Kadmon Holdings' Earnings History.
Where is Kadmon Holdings' stock going? Where will Kadmon Holdings' stock price be in 2017?
6 brokers have issued twelve-month price objectives for Kadmon Holdings' stock. Their forecasts range from $3.25 to $25.00. On average, they expect Kadmon Holdings' share price to reach $13.54 in the next twelve months. View Analyst Ratings for Kadmon Holdings.
What are analysts saying about Kadmon Holdings stock?
Here are some recent quotes from research analysts about Kadmon Holdings stock:
- 1. According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (6/20/2017)
- 2. Citigroup Inc. analysts commented, "We believe investors could find a better de-risked entry point in the next 12–18 months with more data as we see long term upside," analyst Robyn Karnauskas wrote in a note.Related Link: "Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality," H.C. Wainwright Says"While we note 40–100 percent upside if every POC trial works, the stock could trade at $3–$5/sh (50–70 percent downside) if Tesevatinib fails in cancer trials & could trade at cash ($1/sh) if KD-025 also fails due to safety," the analyst continued.Karnauskas noted that the company may face cash crunch beyond first–second quarter of 2017 and they may be at risk of going to capital markets again before majority of data readout in the second half of 2017.That said, the analyst is positive on the Tesevatinib cancer program, as it crosses the blood brain barrier."We see FV of this program at $9/sh (75 percent of our valuation) and model 35 percent probability to brain met NSCLC opportunity ($400 million peak unadjusted) and 25 percent probability to GBM opportunity ($800 million peak unadjusted)," (8/22/2016)
Who are some of Kadmon Holdings' key competitors?
Some companies that are related to Kadmon Holdings include Sinovac Biotech (SVA), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Kamada (KMDA), Mereo BioPharma Group PLC (MPH), Peregrine Pharmaceuticals (PPHM), Cardiome Pharma Corporation (CRME), Strongbridge Biopharma PLC (SBBP), Vericel Corporation (VCEL), Alimera Sciences (ALIM), Kalvista Pharmaceuticals (KALV), Tokai Pharmaceuticals (NVUS), Chiasma (CHMA), Mirna Therapeutics (MIRN), Cesca Therapeutics (KOOL), Sonoma Pharmaceuticals (SNOA), Ocera Therapeutics (OCRX) and Argos Therapeutics (ARGS).
When did Kadmon Holdings IPO?
(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Who owns Kadmon Holdings stock?
Kadmon Holdings' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (10.00%), Point72 Asset Management L.P. (1.27%), Vanguard Group Inc. (1.09%), Beach Point Capital Management LP (0.49%), JPMorgan Chase & Co. (0.44%) and AE Wealth Management LLC (0.21%). Company insiders that own Kadmon Holdings stock include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov. View Institutional Ownership Trends for Kadmon Holdings.
Who sold Kadmon Holdings stock? Who is selling Kadmon Holdings stock?
Who bought Kadmon Holdings stock? Who is buying Kadmon Holdings stock?
Kadmon Holdings' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Vanguard Group Inc., JPMorgan Chase & Co., AE Wealth Management LLC, Nationwide Fund Advisors, Renaissance Technologies LLC, Bank of New York Mellon Corp and KCG Holdings Inc.. Company insiders that have bought Kadmon Holdings stock in the last two years include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov. View Insider Buying and Selling for Kadmon Holdings.
How do I buy Kadmon Holdings stock?
Shares of Kadmon Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon Holdings' stock price today?
MarketBeat Community Rating for Kadmon Holdings (NASDAQ KDMN)MarketBeat's community ratings are surveys of what our community members think about Kadmon Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Kadmon Holdings stock can currently be purchased for approximately $3.38.
Consensus Ratings for Kadmon Holdings (NASDAQ:KDMN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$13.54 (300.64% upside)|
Analysts' Ratings History for Kadmon Holdings (NASDAQ:KDMN)
(Data available from 6/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/27/2017||Citigroup Inc.||Lower Price Target||Neutral||$6.00 -> $4.00||High|
|3/23/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$36.10 -> $23.00||Low|
|3/16/2017||WBB Securities||Upgrade||Sell -> Hold||$3.25||Medium|
|2/1/2017||HC Wainwright||Reiterated Rating||Buy||$25.00||N/A|
|11/21/2016||JMP Securities||Reiterated Rating||Buy||N/A|
|11/10/2016||Jefferies Group LLC||Reiterated Rating||Buy||$12.00 -> $10.00||N/A|
Earnings History for Kadmon Holdings (NASDAQ:KDMN)Earnings History by Quarter for Kadmon Holdings (NASDAQ KDMN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/15/2017||Q1 2017||($0.52)||($0.39)||$4.25 million||$5.60 million||View||N/A|
|3/22/2017||Q4 2016||($0.71)||($0.50)||$4.50 million||$4.28 million||View||N/A|
|11/9/2016||Q3 2016||($0.40)||($4.23)||$3.90 million||$5.70 million||View||N/A|
Earnings Estimates for Kadmon Holdings (NASDAQ:KDMN)
2017 EPS Consensus Estimate: ($1.83)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Kadmon Holdings (NASDAQ:KDMN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Kadmon Holdings (NASDAQ:KDMN)Insider Trades by Quarter for Kadmon Holdings (NASDAQ:KDMN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/13/2017||Daniel S Loeb||Major Shareholder||Buy||1,488,095||$3.36||$4,999,999.20|| |
|11/16/2016||Harlan Waksal||CEO||Buy||2,000||$6.37||$12,740.00|| |
|11/14/2016||Harlan Waksal||CEO||Buy||2,000||$6.79||$13,580.00|| |
|11/11/2016||Konstantin Poukalov||CFO||Buy||4,000||$5.81||$23,240.00|| |
|9/14/2016||Daniel S Loeb||Major Shareholder||Buy||19,611||$7.79||$152,769.69|| |
|9/13/2016||Daniel S Loeb||Major Shareholder||Buy||68,654||$8.33||$571,887.82|| |
|9/6/2016||Daniel S Loeb||Major Shareholder||Buy||81,781||$9.39||$767,923.59|| |
|8/26/2016||Daniel S Loeb||Major Shareholder||Buy||32,916||$9.98||$328,501.68|| |
|8/22/2016||Daniel S Loeb||Major Shareholder||Buy||11,305||$10.00||$113,050.00|| |
|8/15/2016||Daniel S Loeb||Major Shareholder||Buy||6,010||$9.95||$59,799.50|| |
|8/12/2016||Daniel S Loeb||Major Shareholder||Buy||87,529||$9.98||$873,539.42|| |
|8/5/2016||Daniel S Loeb||Major Shareholder||Buy||66,828||$9.94||$664,270.32|| |
|8/3/2016||Daniel S Loeb||Major Shareholder||Buy||1,431,996||$11.35||$16,253,154.60|| |
|8/1/2016||Goldentree Asset Management Lp||Major Shareholder||Buy||208,333||$12.00||$2,499,996.00|| |
|7/28/2016||Bart M Schwartz||Director||Buy||2,000||$9.77||$19,540.00|| |
Headline Trends for Kadmon Holdings (NASDAQ:KDMN)
Latest Headlines for Kadmon Holdings (NASDAQ:KDMN)
|Kadmon (KDMN) to Present Interim Data on KD025 in cGVHD at R&D Day|
www.streetinsider.com - June 24 at 4:31 AM
|Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day|
finance.yahoo.com - June 23 at 6:30 PM
|ETFs with exposure to Kadmon Holdings, Inc. : June 22, 2017|
finance.yahoo.com - June 23 at 6:55 AM
|BUZZ-US STOCKS ON THE MOVE-Red Hat, CA Inc, AMD, Foot Locker, Signet, La-Z-Boy, Chuy's - Nasdaq|
www.nasdaq.com - June 21 at 3:54 PM
|Kadmon Holdings Inc (KDMN) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - June 20 at 8:54 PM
|ETFs with exposure to Kadmon Holdings, Inc. : June 5, 2017|
finance.yahoo.com - June 5 at 6:51 PM
|Kadmon to Present at the Jefferies 2017 Global Healthcare Conference|
finance.yahoo.com - June 5 at 10:02 AM
|Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017|
finance.yahoo.com - June 2 at 7:32 PM
|Kadmon (KDMN) Says Data Shows Potential of New GLUT Inhibitors for Treatment of Autoimmune and Inflammatory Conditions|
www.streetinsider.com - June 1 at 6:57 PM
|Kadmon (KDMN) Says Data Shows Potential of New GLUT ... - StreetInsider.com|
www.streetinsider.com - June 1 at 6:57 PM
|Kadmon Announces Data Demonstrating the Potential of the Company’s New GLUT Inhibitors for the Treatment of Autoimmune and Inflammatory Conditions|
finance.yahoo.com - June 1 at 6:57 PM
|Kadmon Holdings Inc (KDMN) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - May 26 at 9:04 PM
|Robbins Arroyo LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of ... - Business Wire (press release)|
www.businesswire.com - May 24 at 11:18 AM
|Kadmon Holdings Inc (KDMN) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - May 23 at 11:48 PM
|Robbins Arroyo LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of Shareholders|
finance.yahoo.com - May 22 at 5:33 PM
|Scott+Scott, Attorneys at Law, LLP Announces Investigation of Kadmon Holdings Inc. (KDMN)|
finance.yahoo.com - May 16 at 5:59 PM
|Kadmon Holdings Inc (KDMN) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS|
www.americanbankingnews.com - May 15 at 2:16 PM
|Kadmon Provides Business Update and Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 15 at 10:44 AM
|BRIEF-Kadmon Holdings says CEO Harlan Waksal's total compensation for 2016 was $13.4 mln vs$16.3 mln in 2015 - SEC filing|
www.reuters.com - May 11 at 11:42 PM
|Kadmon to Present Clinical and Preclinical Data Highlighting the Role of ROCK2 Signaling in Immune System Function at AAI Annual Meeting|
finance.yahoo.com - May 11 at 6:38 PM
|Kadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients|
finance.yahoo.com - April 12 at 7:03 PM
|Kadmon Submits Second Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA|
finance.yahoo.com - April 7 at 10:40 AM
|Kadmon Holdings Inc (KDMN) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - April 4 at 6:10 PM
|Kadmon Announces Amendment to Credit Agreement and Related Warrants|
finance.yahoo.com - April 4 at 6:03 AM
|KADMON HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial|
biz.yahoo.com - April 4 at 6:03 AM
|Kadmon Holdings Inc (KDMN) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - April 1 at 3:30 PM
|KADMON HOLDINGS, INC. Financials|
finance.yahoo.com - March 28 at 5:44 PM
|Kadmon (KDMN) Presents Preclinical Data Supporting Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis|
www.streetinsider.com - March 28 at 10:57 AM
|Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis|
us.rd.yahoo.com - March 28 at 10:57 AM
|Kadmon Holdings Inc (KDMN) Price Target Lowered to $4.00 at Citigroup Inc|
www.americanbankingnews.com - March 27 at 9:20 AM
|Q1 2017 Earnings Forecast for Kadmon Holdings Inc (KDMN) Issued By Jefferies Group|
www.americanbankingnews.com - March 27 at 8:14 AM
|Kadmon Holdings Inc to Post FY2021 Earnings of ($0.66) Per Share, Jefferies Group Forecasts (KDMN)|
www.americanbankingnews.com - March 24 at 2:28 PM
|Kadmon Holdings Inc (KDMN) Given Overweight Rating at Piper Jaffray Companies|
www.americanbankingnews.com - March 23 at 5:10 PM
|Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results|
us.rd.yahoo.com - March 22 at 6:20 PM
|Kadmon Holdings Inc (KDMN) Rating Increased to Hold at WBB Securities|
www.americanbankingnews.com - March 22 at 10:38 AM
|Bloomberg Markets: Dave Wilson’s Stock of the Day for March 20|
www.bloomberg.com - March 21 at 12:11 PM
|Coverage initiated on Kadmon Holdings by Piper Jaffray|
us.rd.yahoo.com - March 14 at 5:19 PM
|KADMON HOLDINGS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Unregistered Sale of Equity S|
biz.yahoo.com - March 9 at 8:25 AM
|Kadmon Announces Approximately $23 Million Equity Financing|
us.rd.yahoo.com - March 8 at 6:53 PM
|Kadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC - StreetInsider.com|
www.streetinsider.com - December 8 at 10:21 AM
|Kadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC|
www.streetinsider.com - December 7 at 10:28 AM
|Kadmon (KDMN) Submits ANDA for KD034|
www.streetinsider.com - December 6 at 10:23 AM
|Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases|
us.rd.yahoo.com - December 6 at 10:23 AM
|8:31 am Kadmon Holdings announces data from its ongoing Phase 2 clinical study of tesevatinib for the treatment of epidermal growth factor receptor NSCLC that has metastasized to the brain and/or the leptomeninges|
us.rd.yahoo.com - December 6 at 10:23 AM
|Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA - Business Wire (press release)|
www.businesswire.com - December 5 at 6:22 PM
|4:01 pm Kadmon Holdings submits ANDA for KD034 - first application submitted to the FDA for a generic trientine hydrochloride product for the treatment of Wilson's disease|
finance.yahoo.com - December 5 at 6:22 PM
|Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA|
finance.yahoo.com - December 5 at 6:22 PM
|Kadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference|
finance.yahoo.com - November 29 at 4:20 PM
|Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ... - Business Wire (press release)|
www.businesswire.com - November 21 at 10:56 AM
|Form 424B3 Kadmon Holdings, Inc. - StreetInsider.com|
www.streetinsider.com - November 21 at 10:56 AM
Kadmon Holdings (KDMN) Chart for Saturday, June, 24, 2017